RU2017109818A3 - - Google Patents

Download PDF

Info

Publication number
RU2017109818A3
RU2017109818A3 RU2017109818A RU2017109818A RU2017109818A3 RU 2017109818 A3 RU2017109818 A3 RU 2017109818A3 RU 2017109818 A RU2017109818 A RU 2017109818A RU 2017109818 A RU2017109818 A RU 2017109818A RU 2017109818 A3 RU2017109818 A3 RU 2017109818A3
Authority
RU
Russia
Application number
RU2017109818A
Other languages
Russian (ru)
Other versions
RU2017109818A (ru
RU2672569C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017109818A publication Critical patent/RU2017109818A/ru
Publication of RU2017109818A3 publication Critical patent/RU2017109818A3/ru
Application granted granted Critical
Publication of RU2672569C2 publication Critical patent/RU2672569C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2017109818A 2014-08-27 2015-08-27 Новое производное оксима хромона и его использование в качестве аллостерического модулятора метаботропных рецепторов глутамата RU2672569C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14182468.0 2014-08-27
EP14182468 2014-08-27
PCT/EP2015/069601 WO2016030444A1 (en) 2014-08-27 2015-08-27 Novel chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors

Publications (3)

Publication Number Publication Date
RU2017109818A RU2017109818A (ru) 2018-10-01
RU2017109818A3 true RU2017109818A3 (enExample) 2018-10-01
RU2672569C2 RU2672569C2 (ru) 2018-11-16

Family

ID=51421865

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017109818A RU2672569C2 (ru) 2014-08-27 2015-08-27 Новое производное оксима хромона и его использование в качестве аллостерического модулятора метаботропных рецепторов глутамата

Country Status (26)

Country Link
US (3) US10017521B2 (enExample)
EP (3) EP3502115A1 (enExample)
JP (1) JP6430015B2 (enExample)
KR (1) KR101870589B1 (enExample)
CN (2) CN106715444B (enExample)
AU (1) AU2015308438B2 (enExample)
CA (1) CA2956191C (enExample)
CY (1) CY1121352T1 (enExample)
DK (1) DK3186257T3 (enExample)
ES (1) ES2714073T3 (enExample)
HR (1) HRP20190343T1 (enExample)
HU (1) HUE041941T2 (enExample)
IL (1) IL250287B (enExample)
LT (1) LT3186257T (enExample)
MA (3) MA48048A (enExample)
ME (1) ME03339B (enExample)
MX (1) MX369643B (enExample)
NZ (1) NZ728853A (enExample)
PL (1) PL3186257T3 (enExample)
PT (1) PT3186257T (enExample)
RS (1) RS58592B1 (enExample)
RU (1) RU2672569C2 (enExample)
SI (1) SI3186257T1 (enExample)
SM (1) SMT201900152T1 (enExample)
TR (1) TR201903332T4 (enExample)
WO (1) WO2016030444A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900152T1 (it) 2014-08-27 2019-05-10 Prexton Therapeutics Sa Nuovo derivato di cromone ossima e suo uso come modulatore allosterico di recettori metabotropici del glutammato
AU2016313138A1 (en) * 2015-08-27 2018-03-15 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
IL280213B2 (en) 2018-07-26 2024-06-01 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065467A (en) 1973-12-27 1977-12-27 Carlo Erba, S. P. A. 5:6-Benzo δ-pyrone derivatives and process for their preparation
US4777252A (en) 1987-08-13 1988-10-11 E. R. Squibb & Sons, Inc. 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
JP3993651B2 (ja) 1994-10-21 2007-10-17 アスビオファーマ株式会社 シクロプロパクロメンカルボン酸誘導体
EP1298129A3 (en) 2001-09-28 2003-06-04 Central Glass Company, Limited Process for producing 4-sustituted benzopyran derivatives
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
JP2006522124A (ja) 2003-04-03 2006-09-28 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用な組成物
WO2007011701A1 (en) 2005-07-15 2007-01-25 Transform Pharmaceuticals, Inc. Novel hydrochloride salts of levodopa
WO2009010455A2 (en) 2007-07-13 2009-01-22 Addex Pharma S.A. Pyrazole derivatives as modulators of metabotropic glutamate receptors
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
JP5806672B2 (ja) * 2009-10-30 2015-11-10 ドメイン・セラピューティクス 新規オキシム誘導体及び代謝型グルタミン酸受容体のアロステリック調節因子としての利用
KR102074089B1 (ko) * 2009-12-04 2020-02-05 선오비온 파마슈티컬스 인코포레이티드 다환형 화합물 및 이의 사용 방법
US20140349994A1 (en) * 2012-01-18 2014-11-27 Addex Pharma S.A. Novel 2-Amino-4,5,6,8-Tetrahydropyrazolo[3,4-b]Thiazolo [4,5-d]Azepine Derivatives and Their Use as Allosteric Modulators of Metabotropic Glutamate Receptors
SMT201900152T1 (it) * 2014-08-27 2019-05-10 Prexton Therapeutics Sa Nuovo derivato di cromone ossima e suo uso come modulatore allosterico di recettori metabotropici del glutammato
AU2016313138A1 (en) 2015-08-27 2018-03-15 Prexton Therapeutics Sa Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia

Also Published As

Publication number Publication date
CN110343118A (zh) 2019-10-18
HUE041941T2 (hu) 2019-06-28
US10442818B2 (en) 2019-10-15
RU2017109818A (ru) 2018-10-01
SMT201900152T1 (it) 2019-05-10
MA40530A (fr) 2017-07-05
CA2956191A1 (en) 2016-03-03
ME03339B (me) 2019-10-20
EP3186257A1 (en) 2017-07-05
DK3186257T3 (en) 2019-04-01
IL250287B (en) 2020-02-27
TR201903332T4 (tr) 2019-03-21
WO2016030444A1 (en) 2016-03-03
RS58592B1 (sr) 2019-05-31
IL250287A0 (en) 2017-03-30
US20180291034A1 (en) 2018-10-11
CN106715444B (zh) 2019-07-12
AU2015308438B2 (en) 2018-12-13
RU2672569C2 (ru) 2018-11-16
MX2017002429A (es) 2017-08-02
KR101870589B1 (ko) 2018-06-25
JP2017525776A (ja) 2017-09-07
AU2015308438A1 (en) 2017-03-02
EP3186257B1 (en) 2019-02-06
NZ728853A (en) 2018-04-27
US20170253613A1 (en) 2017-09-07
MA52702A (fr) 2021-03-31
SI3186257T1 (sl) 2019-07-31
CN106715444A (zh) 2017-05-24
US20200024285A1 (en) 2020-01-23
PL3186257T3 (pl) 2019-07-31
ES2714073T3 (es) 2019-05-27
LT3186257T (lt) 2019-04-25
MX369643B (es) 2019-11-15
MA48048A (fr) 2020-02-12
EP3502115A1 (en) 2019-06-26
PT3186257T (pt) 2019-03-27
HRP20190343T1 (hr) 2019-05-31
JP6430015B2 (ja) 2018-11-28
KR20170042624A (ko) 2017-04-19
EP3696183A1 (en) 2020-08-19
CA2956191C (en) 2020-01-28
US10017521B2 (en) 2018-07-10
CY1121352T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
BR112016017520A2 (enExample)
BR112016016951A2 (enExample)
BR112016016756A2 (enExample)
BR112016016478A2 (enExample)
BR112016016978A2 (enExample)
BR112016018948A2 (enExample)
BR112016015605A2 (enExample)
BR112016017262A2 (enExample)
BR112016016933A2 (enExample)
BR112016016364A2 (enExample)
BR112016017713A2 (enExample)
BR112016016298A2 (enExample)
BR112016018944A2 (enExample)
BR112016015645A2 (enExample)
BR112016016149A2 (enExample)
BR112016016534A2 (enExample)
BR112016018043A2 (enExample)
BR112016016601A2 (enExample)
BR112016015552A2 (enExample)
BR112016016575A2 (enExample)
BR112016017717A2 (enExample)
BR112016015797A2 (enExample)
BR112016019051A2 (enExample)
BR112016016442A2 (enExample)
BR112016016139A2 (enExample)

Legal Events

Date Code Title Description
HE4A Change of address of a patent owner

Effective date: 20190619